Get the Stockscreener App
30.19
0.97%
0.29
Pre-market:
30.60
0.41
+1.36%
Stoke Therapeutics Inc stock is traded at $30.19, with a volume of 1.33M.
It is up +0.97% in the last 24 hours and up +33.23% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$29.90
Open:
$30.95
24h Volume:
1.33M
Relative Volume:
1.35
Market Cap:
$1.65B
Revenue:
$199.89M
Net Income/Loss:
$52.48M
P/E Ratio:
35.52
EPS:
0.85
Net Cash Flow:
$61.15M
1W Performance:
+18.11%
1M Performance:
+33.23%
6M Performance:
+363.04%
1Y Performance:
+164.82%
1-Day Range:
$28.40
$31.21
1-Week Range:
$25.95
$32.40
52-Week Range:
$5.35
$32.40
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
30.19 | 1.64B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Can Stoke Therapeutics Inc. rally from current levelsGlobal Markets & Stepwise Trade Execution Plans - newser.com
Is a relief rally coming for Stoke Therapeutics Inc. holders2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
Stoke Therapeutics Hits New 52-Week High at $32.40, Up 104.84% - Markets Mojo
Edward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Needham & Company LLC - MarketBeat
Why Stoke Therapeutics (STOK) Is Up 18.1% After Positive Three-Year Data for Dravet Syndrome Therapy - simplywall.st
Stoke therapeutics director Kaye sells $750,000 in shares By Investing.com - Investing.com South Africa
Stoke therapeutics director Kaye sells $750,000 in shares - Investing.com
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Needham raises Stoke Therapeutics stock price target to $35 on positive trial data - Investing.com Canada
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
What is Leerink Partnrs' Estimate for STOK FY2027 Earnings? - MarketBeat
Needham Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Needham Raises Stoke Therapeutics (STOK) Price Target by 59.09% to $35 | STOK Stock News - GuruFocus
Will Stoke Therapeutics Inc. price bounce be sustainableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How to integrate Stoke Therapeutics Inc. into portfolio analysis tools - newser.com
Using data tools to time your Stoke Therapeutics Inc. exitJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome - Yahoo
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th - GlobeNewswire
Biogen Inc. - Via Ritzau
Stoke Therapeutics Hits Day High with 11.68% Surge in Stock Price - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39% - simplywall.st
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 39% But Its Business Still Trails The Industry - 富途牛牛
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance
Detecting price anomalies in Stoke Therapeutics Inc. with AIRate Cut & Fast Gain Swing Trade Alerts - newser.com
What the charts say about Stoke Therapeutics Inc. todayGlobal Markets & Real-Time Stock Entry Alerts - newser.com
Signal strength of Stoke Therapeutics Inc. stock in tech scannersEarnings Risk Summary & Reliable Trade Execution Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss Ratings - MarketBeat
Will Stoke Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Stoke Therapeutics’ Stock Climbs: What’s Next? - timothysykes.com
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Stoke Therapeutics stock hits 52-week high at 28.03 USD By Investing.com - Investing.com Canada
Stoke Therapeutics stock hits 52-week high at 28.03 USD - Investing.com
Stoke Therapeutics Hits New 52-Week High at $28.00, Up 80% - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 Shares - MarketBeat
Stoke Therapeutics Appoints Ian F. Smith as CEO - The Globe and Mail
Stoke Therapeutics Hits New 52-Week High of $25.61, Up 71.66% - Markets Mojo
Stoke Therapeutics appoints Ian Smith as permanent CEO By Investing.com - Investing.com Canada
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month HighStill a Buy? - MarketBeat
Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer - MarketScreener
Stoke Therapeutics Inc.’s volatility index tracking explainedMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Stoke Therapeutics (STOK) Appoints Ian F. Smith as CEO - GuruFocus
Stoke Therapeutics names Ian F. Smith as permanent CEO and principal executive - Investing.com
Stoke Therapeutics appoints Ian Smith as permanent CEO - Investing.com India
Stoke Therapeutics appoints Ian Smith as chief executive officer - MarketScreener
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD | Director |
Oct 08 '25 |
Sale |
30.00 |
25,000 |
750,000 |
49,124 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):